文献速递临床试验与 GCP基础与转化研究

自体多克隆扩增调节性T细胞治疗新发1型糖尿病儿童的2期随机试验

A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes.
PubMed 文献 · Sci Transl Med · 2024-05-08

这项多中心、双盲、随机2期临床试验将110例新发1型糖尿病儿童和青少年按1:1:1随机分配至高剂量(20×10^6细胞/千克)或低剂量(1×10^6细胞/千克)自体多克隆扩增调节性T细胞(expTregs)或匹配安慰剂,单次输注安全但未阻止1年内残存β细胞功能下降(低剂量P=0.94,高剂量P=0.21)。expTregs体外高度活化且具抑制性,高剂量组输注后1周可检测到活化记忆Tregs短暂增加;expTregs体外扩增倍数个体间存在差异,较低扩增倍数及其相关基因特征与更好的C肽保留相关,与Treg剂量无关。

要点

  • 单次输注expTregs安全,但未阻止1年内残存β细胞功能下降。
  • 高剂量组输注后1周可检测到活化记忆Tregs短暂增加。
  • 较低体外扩增倍数与更好C肽保留相关,与Treg剂量无关。

核心结论

  • 单次剂量多克隆expTregs不改变1型糖尿病进展,Treg质量可能是重要因素。

研究设计与样本

  • 随机、多中心、双盲2期临床试验(Sanford/Lisata Therapeutics T-Rex 2期试验,ClinicalTrials.gov NCT02691247)。
  • 110例接受治疗的新发1型糖尿病儿童和青少年按1:1:1随机分配至高剂量(20×10^6细胞/千克)、低剂量(1×10^6细胞/千克)expTregs或匹配安慰剂。
  • 对选定的expTregs及参与者外周血样本进行流式细胞术以及bulk和单细胞RNA测序。

主要发现

  • 单次剂量expTregs安全,但与安慰剂相比未阻止1年内残存β细胞功能下降(低剂量P=0.94,高剂量P=0.21),与年龄或基线C肽无关。
  • expTregs体外高度活化且具抑制性。
  • 高剂量组输注后1周可检测到活化记忆Tregs短暂增加,提示expTregs有效转移。
  • expTregs体外扩增倍数在参与者间存在差异,即使考虑年龄因素后仍存在;较低扩增倍数及其相关基因特征与更好的C肽保留相关,与Treg剂量无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD4+CD25hiCD127lo/-FOXP3+ regulatory T cells (Tregs) play a key role in preventing autoimmunity. In autoimmune type 1 diabetes (T1D), adoptive transfer of autologous polyclonal Tregs has been shown to be safe in adults in phase 1 clinical trials. We explored factors contributing to efficacy of autologous polyclonal expanded Tregs (expTregs) in a randomized phase 2 multi-center, double-blind, clinical trial (Sanford/Lisata Therapeutics T-Rex phase 2 trial, ClinicalTrials.gov NCT02691247). One hundred ten treated children and adolescents with new-onset T1D were randomized 1:1:1 to high-dose (20 × 106 cells/kilogram) or low-dose (1 × 106 cells/kilogram) treatments or to matching placebo. Cytometry as well as bulk and single-cell RNA sequencing were performed on selected expTregs and peripheral blood samples from participants. The single doses of expTregs were safe but did not prevent decline in residual β cell function over 1 year compared to placebo (P = 0.94 low dose, P = 0.21 high dose), regardless of age or baseline C-peptide. ExpTregs were highly activated and suppressive in vitro. A transient increase of activated memory Tregs was detectable 1 week after infusion in the high-dose cohort, suggesting effective transfer of expTregs. However, the in vitro fold expansion of expTregs varied across participants, even when accounting for age, and lower fold expansion and its associated gene signature were linked with better C-peptide preservation regardless of Treg dose. These results suggest that a single dose of polyclonal expTregs does not alter progression in T1D; instead, Treg quality may be an important factor.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Bender C, Wiedeman AE, Hu A, et al. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes. Sci Transl Med. 2024. PMID: 38718135. doi:10.1126/scitranslmed.adn2404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。